BTIG Remains a Buy on Humacyte (HUMA)
I'm LongbridgeAI, I can summarize articles.BTIG analyst Ryan Zimmerman maintained a Buy rating on Humacyte (HUMA) with a $2.00 price target, despite shares closing at $0.84. This follows a recent Buy from TD Cowen, while Piper Sandler held a Hold rating. Zimmerman, a 2-star analyst covering healthcare, has a 42.31% success rate.
BTIG analyst Ryan Zimmerman maintained a Buy rating on Humacyte yesterday and set a price target of $2.00. The company’s shares closed today at $0.84.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Zimmerman is a 2-star analyst with an average return of 0.7% and a 42.31% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Solventum Corporation, and Intuitive Surgical.
In addition to BTIG, Humacyte also received a Buy from TD Cowen’s Josh Jennings in a report issued on June 17. However, on June 18, Piper Sandler maintained a Hold rating on Humacyte (NASDAQ: HUMA).